165 results on '"Yung, Thomas"'
Search Results
2. Bothersome Hot Flashes Following Neoadjuvant Androgen Deprivation Therapy and Stereotactic Body Radiotherapy for Localized Prostate Cancer
Catalog
Books, media, physical & digital resources
3. Prognostic utility of biopsy-based PTEN and ERG status on biochemical progression and overall survival after SBRT for localized prostate cancer.
4. Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes
5. Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer
6. 1368: Radiation-related lymphopenia post prostate stereotactic body radiation therapy ± pelvic irradiation
7. Utilization of patient-reported outcomes to assess adherence to relugolix when combined with radiation therapy.
8. Maintenance of patient-reported quality of life (EQ-5D-3L) post neoadjuvant relugolix prior to the initiation of prostate radiation therapy.
9. 99: Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavourable Prostate Cancer: Fvie-Year Outcomes
10. Evaluation of Four Fully Integrated Molecular Assays for the Detection of Respiratory Viruses during the Co-Circulation of SARS-CoV-2, Influenza and RSV
11. 713: Low incidence of high-grade lymphopenia following radiotherapy for oligometastatic prostate cancer
12. Patient-Reported Financial Burden Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer
13. Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer
14. Efficient Online 4D Magnetic Resonance Imaging
15. Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy
16. Translation‐dependent mechanisms lead to PML upregulation and mediate oncogenic K‐RAS‐induced cellular senescence
17. Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer
18. Ten-Year Single Institutional Analysis of Geographic and Demographic Characteristics of Patients Treated With Stereotactic Body Radiation Therapy for Localized Prostate Cancer
19. Monitoring of quality indicators for detection of mycobacteria in clinical laboratories
20. A CK2-Dependent Mechanism for Degradation of the PML Tumor Suppressor
21. Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer
22. Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15)
23. Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP)
24. Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)
25. Management of isolated local failures following stereotactic body radiation therapy for low to intermediate risk prostate cancer.
26. Predictors of prostate cancer-specific anxiety following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.
27. Self-reported burden in patients with localized prostate cancer treated with stereotactic body radiation therapy (SBRT).
28. Patient-reported anxiety with localized prostate cancer treated with stereotactic body radiation therapy (SBRT).
29. Urinary toxicity in men treated with stereotactic body radiation therapy (SBRT) for localized prostate cancer following procedures for benign prostatic hyperplasia (BPH).
30. Utilization of Patient-Reported Outcomes to Guide Symptom Management during Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer
31. Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?
32. Predictors of acute urinary symptom flare following stereotactic body radiation therapy (SBRT) in the definitive treatment of localized prostate cancer
33. Prostate specific antigen five years following stereotactic body radiation therapy (SBRT) for low and intermediate risk prostate cancer: An ablative procedure?
34. Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity
35. Suivi des indicateurs qualité pour la recherche de mycobactéries dans les laboratoires de biologie médicale.
36. Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial Design
37. The Impact of Obesity on Patient Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer
38. Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction
39. Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience
40. Urethrogram-Directed Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer in Patients with Contraindications to Magnetic Resonance Imaging
41. Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
42. Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?
43. Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer
44. Proctitis following stereotactic body radiation therapy for prostate cancer
45. Improved Irritative Voiding Symptoms 3 Years after Stereotactic Body Radiation Therapy for Prostate Cancer
46. Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer
47. Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer
48. Clinical Characteristics and Management of Late Urinary Symptom Flare Following Stereotactic Body Radiation Therapy for Prostate Cancer
49. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer
50. Bother following stereotactic body radiation therapy for clinically localized prostate cancer.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.